1 citations,
January 2007 in “Side effects of drugs annual” Dermatological treatments can have significant side effects, including allergic reactions, sexual dysfunction, and increased cancer risk.
May 2024 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Oral minoxidil 7.5 mg for hair loss increases heart rate but not blood pressure.
May 2022 in “Indian Journal of Pharmacology” Sodium valproate can cause serious high blood pressure in children.
Low-level light therapy may reduce hair loss and improve hair quality but it's unclear who benefits most.
353 citations,
February 2022 in “Nature Immunology” Long-haul COVID can cause lasting symptoms affecting many body systems and may be linked to ongoing inflammation and immune system issues.
80 citations,
February 2021 in “Cureus” Many COVID-19 survivors continue to experience symptoms like fatigue and concentration problems after recovery, possibly needing rehabilitation.
4 citations,
June 2022 in “Journal of food bioactives” Eating plant-based anti-inflammatories and antioxidants may help manage long-term COVID-19 health issues.
2 citations,
September 2021 The COVID-19 pandemic increased the use of teledermatology to treat skin conditions in low-income areas, despite challenges like poor photo quality.
April 2024 in “Skin research and technology” Botulinum toxin A has limited effectiveness for 3 months in treating female pattern hair loss and may reduce scalp oiliness.
April 2021 in “European medical journal” A COVID-19 patient had severe and long-lasting skin issues and unusual hair loss.
39 citations,
September 2015 in “Clinical Therapeutics” Teriflunomide was an FDA-approved oral medication for relapsing multiple sclerosis, demonstrating significant efficacy in reducing relapse rates and disease progression in clinical trials. The 14-mg dose notably reduced the annualized relapse rate by up to 36% and decreased disability progression risk, while the 7-mg dose was less effective in preventing disability progression. MRI results supported its efficacy by showing reduced lesion volume. Common adverse events included headache, increased liver enzymes, diarrhea, and alopecia. Due to potential teratogenic effects, it was contraindicated in pregnancy, and routine monitoring was recommended. Overall, teriflunomide was considered an effective treatment option with a favorable benefit-risk profile.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
13 citations,
January 2018 in “International Journal of Trichology” Intralesional triamcinolone injections can effectively stop frontal fibrosing alopecia with minimal side effects.
8 citations,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
4 citations,
May 2022 in “Medicina” Kampo medicine can help treat general fatigue from long COVID.
2 citations,
February 2020 in “Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy” A woman experienced vertigo and hearing loss after weight loss surgery, possibly due to eustachian tube issues from fat loss around ear muscles.
1 citations,
October 2022 in “Journal of Cosmetic Dermatology” Combining microneedling with 2% minoxidil is more effective and safe for treating female pattern hair loss than using minoxidil alone.
1 citations,
January 2022 in “Journal of Cancer Therapy” Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.
1 citations,
August 2021 in “Cosmoderma” Low-dose oral minoxidil is effective and well-tolerated for treating hair loss.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
August 2024 in “Journal of Cosmetic Dermatology” Injectable treatments can effectively and safely improve hair growth in adults with androgenetic alopecia.
August 2024 in “Skin Research and Technology” PRP is an effective and safe treatment for female hair loss.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
May 2023 in “International Journal of Trichology” Low-dose oral Minoxidil is an effective treatment for hair loss with minimal serious side effects.
January 2022 in “Indian journal of drugs in dermatology” Oral minoxidil helps with hair growth but needs more research to fully understand its effectiveness and safety.
December 2020 in “Journal of clinical and investigative dermatology” A man with syphilitic alopecia and neurosyphilis was successfully treated with penicillin, leading to symptom improvement and resolution of hair loss.
May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
January 2023 in “Journal of Cosmetic Dermatology” PRP is effective for treating hair loss, improving hair density, count, and thickness.
January 2019 in “Journal of Cosmetics, Dermatological Sciences and Applications” The combination therapy is safe and effective for treating Female Pattern Hair Loss in Asian women.